ReviewFrontiers in immunology2023
Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Mapping the knowledge domain: a bibliometric analysis of global research on traditional Chinese medicine for non-alcoholic fatty liver disease (2000-2024).Frontiers in medicine · 2026Pooled it
- Targeting Nuclear Import of Thyroid Hormone Receptor Alpha with Natural Polyphenols: Potential Mechanism for Lipolysis in Metabolic Dysfunction-Associated Steatotic Liver Disease.Current issues in molecular biology · 2026Article
- Effect of Jinlong capsule on the survival of patients with hepatocellular carcinoma: a propensity score matching study.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
- Lipophagy in disease: signaling control, organelle communication, and therapeutic opportunities.Cell communication and signaling : CCS · 2026Review
- Article
- Microbiome Modulation withJournal of microbiology and biotechnology · 2026Article
- Longchai Decoction Treated the Fibrosis of Liver Induced by CClJournal of cellular and molecular medicine · 2026Article
- Regulatory mechanisms of Traditional Chinese Medicine on gut microbiota in diabetic microvascular complications.Chinese medicine · 2026Review
- Multi-omics Analysis Revealed the Diagnostic and Therapeutic Value of Immunogenic Cell Death-derived SCN5A in Hepatocellular Carcinoma.Molecular biotechnology · 2026Article
- Multi-target modulation of traditional Chinese medicine based on the liver-gut axis: a new therapeutic strategy for NAFLD.American journal of translational research · 2026Review
- Gut Microbiota Dysbiosis and Metabolite Imbalance Mediate Diabetic Kidney Disease Inflammation: Mechanisms and Intervention Strategies Targeting Gut-Kidney Axis and NF-κB/NLRP3 Pathways.Journal of inflammation research · 2026Review
- Traditional Chinese medicine-based modulation of gut microbiota in coronary heart disease: probiotic synergy and translational perspectives.Frontiers in cardiovascular medicine · 2026Review
- Herbal medicines modulate gut microbiota in metabolic diseases: a review.Frontiers in microbiology · 2026Review
- Functional metagenomic reconstruction of microbial pathways altered by probiotic supplementation in liver failure.Frontiers in cellular and infection microbiology · 2026Article
- Multidimensional mechanisms of natural products in modulating metabolic dysfunction-associated kidney disease: recent advances and future perspectives.Frontiers in pharmacology · 2026Review
- Targeting the gut microbiota: the application and prospects of probiotics, fecal microbiota transplantation, and natural products in MASLD.Frontiers in nutrition · 2026Review
- Traditional Chinese Medicine for Allergic Rhinitis: Mechanisms, Evidence, and Gut-Immune Axis Targets.Journal of asthma and allergy · 2026Review
- Mechanistic roles and intervention strategies involving gut microbiota, amino acid metabolism, and the tumor immune microenvironment in MAFLD-HCC progression.Clinical and experimental medicine · 2025Review
- Based on Network Pharmacology and Gut Microbiota to Explore the Underlying Mechanism of Huangqi Gegen Decoction for Treating Metabolic-Associated Fatty Liver Disease.Food science & nutrition · 2025Article
- In Silico Study of Natural Polyphenols as Potential Metabolic Modulators in Mitigating Lipotoxicity in Non-Alcoholic Fatty Liver Disease via Thyroid Hormone Receptor Alpha Activation.Current issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota not only constitutes intestinal microenvironment homeostasis and human health but also exerts indispensable roles in the occurrence and progression of multiple liver diseases, including alcohol-related liver disease, nonalcoholic fatty liver disease, autoimmune liver disease and liver cancer. Given the therapeutic status of these diseases, their prevention and early therapy are crucial, and the detailed mechanism of gut microbiota in liver disease urgently needs to be explored. Meanwhile, multiple studies have shown that various traditional Chinese medicines, such as Si Miao Formula, Jiangzhi Granules, Liushen Capsules, Chaihu-Shugan Power, Cassiae Semen and Gynostemma, as well as some natural products, including Costunolide, Coprinus comatus polysaccharide, Antarctic krill oil, Oridonin and Berberine, can repair liver injury, improve fatty liver, regulate liver immunity, and even inhibit liver cancer through multiple targets, links, and pathways. Intriguingly, the aforementioned effects demonstrated by these traditional Chinese medicines and natural products have been shown to be closely related to the gut microbiota, directly driving the strategy of traditional Chinese medicines and natural products to regulate the gut microbiota as one of the breakthroughs in the treatment of liver diseases. Based on this, this review comprehensively summarizes and discusses the characteristics, functions and potential mechanisms of these medicines targeting gut microbiota during liver disease treatment. Research on the potential effects on gut microbiota and the regulatory mechanisms of traditional Chinese medicine and natural products provides novel insights and significant references for developing liver disease treatment strategies. In parallel, such explorations will enhance the comprehension of traditional Chinese medicine and natural products modulating gut microbiota during disease treatment, thus facilitating their clinical investigation and application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.